Immunovant, Inc. IMVT Ratios & Valuation
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -64.8%+4.5pp | -69.3%+26.6pp | -95.9%-18.4pp | -77.6%-15.1pp | -62.5%+11.7pp | |
| Return on assets | -58.3%+4.7pp | -63%+21.6pp | -84.6%-13.1pp | -71.5%-14.1pp | -57.4%+10.2pp | |
| Liquidity | ||||||
| Current ratio | 9.1×-6.7× | 15.7×+6.7× | 9.1×-3.3× | 12.3×+1.2× | 11.2×+5.1× | |
| Quick ratio | 9.1×-6.7× | 15.7×+6.7× | 9.1×-3.3× | 12.3×+1.2× | 11.2×+5.1× | |
| Cash ratio | 8.6×-6.4× | 15×+6.8× | 8.3×-3.1× | 11.3×+0.9× | 10.4×+4.9× | |
| Leverage | ||||||
| Interest coverage | -19×-0.9× | -18.1×+0.7× | -18.7×-1.1× | -17.7×-2.0× | -15.7×-2.1× | |
| Per Share | ||||||
| Book value per share | $4.67-14.0% | $5.43+81.5% | $2.99-16.0% | $3.56-23.7% | $4.67+94.5% | |
| Valuation | ||||||
| Market capitalization | $5.06B-1.3% | $5.12B+82.3% | $2.81B+2.8% | $2.73B-5.8% | $2.9B-20.2% | |
| Price / book | 5.9×+0.7× | 5.2×-0.2× | 5.4×+0.9× | 4.5×+0.4× | 4.1×-6.2× | |
| Free cash flow yield | -8.1%+0.2pp | -8.3%+7.1pp | -15.4%-0.1pp | -15.3%-2.3pp | -13%-4.0pp | |
| Earnings yield | -10%-0.9pp | -9.1%+7.5pp | -16.5%-0.2pp | -16.4%-2.1pp | -14.3%-3.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immunovant, Inc.'s ratios come from?
- Every ratio is computed from Immunovant, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.